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Summary
Background Frailty, a state of increased vulnerability to adverse health outcomes, is important in diabetes management. 
We aimed to quantify the prevalence of frailty in people with diabetes, and to summarise the association between 
frailty and generic outcomes (eg, mortality) and diabetes-specific outcomes (eg, hypoglycaemia).
Methods In this systematic review and study-level meta-analysis, we searched MEDLINE, Embase, and Web of Science 
for observational studies published between Jan 1, 2001 (the year of the original publication of the Fried frailty 
phenotype), to Nov 26, 2019. We included studies that assessed and quantified frailty in adults with diabetes, aged 
18 years and older; and excluded conference abstracts, grey literature, and studies not published in English. Data from 
eligible studies were extracted using a piloted data extraction form. Our primary outcome was the prevalence of frailty 
in people with diabetes. Secondary outcomes were incidence of frailty and generic and diabetes-specific outcomes. 
Data were assessed by random-effects meta-analysis where possible and by narrative synthesis where populations were 
too heterogeneous to allow meta-analysis. This study is registered with PROSPERO, CRD42020163109.
Findings Of the 3038 studies we identified, 118 studies using 20 different frailty measures were eligible for inclusion 
(n=1 375 373). The most commonly used measures of frailty were the frailty phenotype (69 [58%] of 118 studies), frailty 
(16 [14%]), and FRAIL scale (10 [8%]). Studies were heterogenous in setting (88 studies were community-based, 18 were 
outpatient-based, ten were inpatient-based, and two were based in residential care facilities), demographics, and 
inclusion criteria; therefore, we could not do a meta-analysis for the primary outcome and instead summarised 
prevalence data using a narrative synthesis. Median community frailty prevalence using frailty phenotype was 
13% (IQR 9–21). Frailty was consistently associated with mortality in 13 (93%) of 14 studies assessing this outcome 
(pooled hazard ratio 1·51 [95% CI 1·30–1·76]), with hospital admission in seven (100%) of seven, and with disability 
in five (100%) of five studies. Frailty was associated with hypoglycaemia events in one study (<1%), microvascular and 
macrovascular complications in nine (82%) of 11 studies assessing complications, lower quality of life in three (100%) of 
three studies assessing quality of life, and cognitive impairment in three (100%) of three studies assessing cognitive 
impairment. 13 (11%) of 118 studies assessed glycated haemoglobin finding no consistent relationship with frailty.
Interpretation The identification and assessment of frailty should become a routine aspect of diabetes care. The 
relationship between frailty and glycaemia, and the effect of frailty in specific groups (eg, middle-aged [aged <65 years] 
people and people in low-income and lower-middle-income countries) needs to be better understood to enable 
diabetes guidelines to be tailored to individuals with frailty.
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Introduction
Clinicians and health-care systems worldwide are facing 
the challenges associated with ageing populations. Dia-
betes (type 1 and type 2) is prevalent in up to 30% of people 
older than 65 years.1 Frailty is a key concept for health care, 
particularly as people age.2 Frailty describes a dynamic 
state of increased vulnerability to adverse health outcomes 
resulting from loss of physio logical reserve.2 The prevalence 
of frailty increases with increasing age.2 However, frailty is 
not universal among older people (aged >65 years), and 
can also be identified in younger people (aged <65 years), 
particularly in the context of long-term conditions, 
including diabetes.3,4
The importance of frailty is increasingly recognised in 
clinical guidelines for diabetes management.5,6 Specifi-
cally, more relaxed glycated haemoglobin (HbA1c) targets 
are recommended among people who are older or 
frail.6 These recommendations are based on lower life 
expectancy and greater risks of hypoglycaemia in older or 
frail individuals.5 However, guidelines are not explicit 
about to whom these recommendations should be 
applied. Frailty is not a single homogeneous concept, and 
there is no single standard definition or measure.2 
Instead, multiple operational definitions of frailty exist.7 
Some are based on characteristics which are measured 
directly (frailty measures based on physical assessments 
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such as grip strength and walking pace) or self-reported 
measures, and others on past medical records. Definitions 
also vary in their inclusion of cognitive status, social 
vulner ability, and functional disability.8 Differences in the 
definition and identi fication of frailty can alter the clinical 
implications for management.9
There is, therefore, uncertainty as to how frailty should 
be identified, measured, and managed, including in the 
context of diabetes. Because of the complex and multi-
faceted nature of frailty, understanding its relationship 
with a broad range of outcomes is important to inform 
clinical decision making around care and treatment. This 
systematic review aims to: first, identify frailty measures 
that have been used to identify frailty in people with 
diabetes; second, quantify the prevalence of frailty in 
people with diabetes; and, third, summarise the association 
between frailty and generic outcomes (eg, mortality), and 
diabetes-specific clinical outcomes (eg, hypoglycaemia) in 
the context of diabetes.
Methods
Search strategy and selection criteria
We did a systematic review and study-level meta-analysis 
of observational studies assessing frailty in the context 
of diabetes. Methods were prespecified and reported 
according to Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines. Criteria 
for inclusion are described in detail in the review 
protocol,10 and were deliberately broad in terms of setting, 
frailty definition, and outcomes. We included studies 
done in any setting (com munity, outpatient, inpatient, 
and residen tial care). Cri teria included observational 
studies, including cross-sectional and cohort studies, that 
included adults (≥18 years) with diabetes (any type or 
unspecified) and quantified frailty in participants with 
diabetes, using any frailty measure or definition to allow 
comparison between different methods of identifying 
frailty. Exclusion criteria were grey literature, conference 
abstracts and any studies not published in English.
We searched MEDLINE, Embase, and Web of Science 
databases between Jan 1, 2001 (which was the year of the 
original publication of the Fried frailty phenotype),11 to 
Nov 26, 2019, using keywords and Medical Subject 
Headings. The search structure was “diabetes” and 
“frail” (full search strategy in appendix p 3). We screened 
all titles and abstracts, and assessed full texts of 
all relevant articles for eligibility. We supplemented 
electronic searches by hand-searching reference lists of 
Research in context
Evidence before this study
We searched MEDLINE, Embase, and Web of Science from 
Jan 1, 2001, to Nov 26, 2019, for observational studies published 
in English that assessed frailty in diabetes (type 1, type 2, 
or unspecified) using the terms “diabetes” and associated terms 
and “frail”. We included studies using any frailty measure and 
done in any setting. We did not identify any existing systematic 
reviews that synthesise data on the prevalence of frailty in people 
with diabetes. One review (eight studies) showed increased risks 
of mortality and cardiovascular events in people with diabetes 
and frailty, but did not distinguish between different definitions 
of frailty, nor did it consider other clinical outcomes.
Added value of this study
This study shows that frailty is common in diabetes. However, 
the methods used to identify and define frailty are highly variable 
between studies. Within the same population, some definitions 
(eg, frailty index) identify a higher proportion of people as frail 
than do others (eg, frailty phenotype). Despite this variation in 
measurement, frailty is consistently associated with a range of 
adverse outcomes, including mortality, hospital admission, 
disability, and lower quality of life. Important evidence gaps 
remain. Frailty is present in middle-aged (aged <65 years) and 
older people (>65 years) with diabetes; however, variation in 
prognosis or association with outcomes at different ages has not 
been widely explored. Evidence from lower-income and 
lower-middle-income countries is scarce, which is an important 
gap because of the rising prevalence of diabetes, along with an 
increasing proportion of older people, in many countries. 
The absolute risk of mortality associated with frailty is highly 
variable between studies and frailty definitions. The relationship 
between glycated haemoglobin (HbA1c) and adverse outcomes in 
frail versus non-frail individuals has not been quantified in the 
literature, and only one study has assessed the relationship 
between frailty and hypoglycaemia. These are important 
research gaps, as clinical guidelines recommend different HbA1c 
targets in the context of frailty, and lower life expectancy forms 
part of the rationale for these targets.
Implications of all the available evidence
Identifying and assessing frailty should become a routine 
aspect of diabetes care, which will require frailty screening to 
become embedded within existing protocols and systems for 
managing diabetes. There is also a need for a more nuanced 
understanding of how frailty should be identified and 
characterised, including the implications of the choice of frailty 
measure. This is particularly important if clinicians are to 
identify people likely to benefit from guideline 
recommendations for managing diabetes in the context of 
frailty. As these guidelines focus on glycaemic targets, 
the scarcity of studies exploring the relationship between 
frailty, HbA1c, and clinical outcomes is an important research 
gap. Because frailty is also prevalent in middle-aged people 
with diabetes, there is a need to question and explore the 
clinical implications of frailty across a wider age range, as the 
basis for current guideline recommendations is based on 
observations from older populations.
See Online for appendix
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relevant articles and forward-citation searching using 
Web of Science. All stages of screening, data extraction, 
and quality assessment were done independently by 
two authors (PH and IF, NC, or EB). Discrepancies were 
resolved by consensus and by a third author (NC or EB).
Data analysis
Data from eligible studies were extracted using a piloted 
data extraction form. Differences in data extraction 
between reviewers were resolved by consensus. We 
extracted data for study aims, study, design setting, 
population characteristics (eligibility, recruitment method, 
summary data for age and sex), diabetes type (type 1, 
type 2, unspecified), frailty measure (including whether 
criteria were adapted from the original description of the 
frailty definition), prevalence of frailty in participants 
with diabetes, and the association between frailty and 
clinical outcomes. The risk of bias in the included studies 
was assessed using an adaptation of the Newcastle-Ottawa 
tool to make the questions about exposure specific to 
the assessment of frailty (eg, use of a validated tool) 
(appendix p 5).12
Our primary outcome was prevalence of frailty in people 
with diabetes. Secondary outcomes were incidence of 
frailty, generic health-care associated outcomes (including 
mortality, hospitalisation, health-care utilisation, quality 
of life, disability, cognitive impairment, and depression), 
and diabetes-specific outcomes (glycaemic control, macro-
vascular and microvascular complications).
Estimates of the prevalence of frailty in diabetes are 
likely to vary depending on the characteristics of the 
underlying population (eg, age, sex, and ethnicity), 
definition of diabetes, frailty definition used, adaptations 
to frailty criteria, and study setting. Because of these 
multiple sources of heterogeneity, we did a narrative 
synthesis of prevalence estimates incorporating these 
features. The quality of the included studies (judged 
by the quality assessment) was incorporated into the 
narrative synthesis presented in the text (eg, highlighting 
where samples were unrepresentative and length of 
follow-up).
Due to the high likelihood of residual heterogeneity 
between popu lations and cohort inclusion criteria, we 
did not do a meta-analysis of these estimates.13
Studies reporting the relationship between frailty and 
clinical outcomes in diabetes were synthesised using a 
combination of narrative synthesis and random-effects 
meta-analysis. A meta-analysis was done only when there 
were at least two studies assessing the same outcome, 
using a comparable method of analysis (ie, the same 
statistical approach was used [eg, Cox proportional 
hazard model of time to event data for mortality]). Where 
these studies used the same measure of frailty, 
a summary estimate was calculated and heterogeneity 
assessed using I² statistic. Where different frailty 
measures were used to assess the same outcome, studies 
were grouped by frailty measure and meta-analysed 
in subgroups (prespecified in the protocol).10 Where 
outcomes or analytic approaches were too heterogeneous, 
a narrative synthesis was done and data summarised 
using Harvest plots.14 Harvest plots use bars to represent 
individual studies placed on a matrix to indicate whether 
the studies showed a positive, negative, or neutral associ-
ation with the outcome in question, and allow synthesis 
of heterogeneous outcome data. Data processing and 
analysis was done using R (version 3.6.1). Meta-analyses 
were done using RevMan5.
This study is registered with PROSPERO, 
CRD42020163109.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
After screening 3038 records, we identified 118 (which 
included 106 cohorts and samples) that met our inclusion 
criteria (1 375 373 participants overall; figure 1). Details of 
each included study are summarised in the appendix 
(pp 12–43).
Figure 1: Study selection
4213 records identified through 
database searching 
3038 total records identified after duplicates removed 
3038 records screened
406 full text articles assessed for eligibility
118 studies included in narrative synthesis
2632 excluded
1218 not observational 
studies
735 conference abstracts
424 not about frailty
255 not on diabetes
31 additional records identified 
through other sources
288 full text articles excluded
107 not assessing frailty in 
diabetes
102 no frailty measure
29 no relevant outcome 
or prevalence estimate
42 review, opinion or 
letter
8 not in English
Articles
e109 www.thelancet.com/healthy-longevity   Vol 1   December 2020
Most studies were community-based population studies 
(88 [75%]), 18 (15%) were outpatient studies, ten (8%) were 
inpatient studies and two (2%) studies were based in 
residential care facilities. Studies were from a wide range 
of geographical locations (appendix p 4). Most studies 
were from high-income (88 [75%] of 118 from 18 countries) 
or from upper-middle-income countries (27 [23%] from 
five countries), three studies (3%) were from three lower-
middle-income countries and none were from low-income 
countries. 25 (21%) of 118 studies included people with 
type 2 diabetes specifically and in 93 (79%) studies the 
type of diabetes was unspecified. 30 (25%) of 118 studies 
specifically recruited people with diabetes, while in the 
remaining 88 (75%) studies, people with diabetes were 
Components Range and categorisation Included 
studies (n)
Outcomes reported in included studies
Frailty phenotype* Five components: unintentional weight loss, exhaustion, 
low grip strength, slow walking pace, and low physical 
activity
1–2 criteria: pre-frail; ≥3 criteria: frail 69 Mortality (n=2); HbA1c (n=1); complications† 
(n=1); cognitive impairment (n=2); 
disability (n=1); QOL (n=1)
Frailty index* Count of health-related deficits (≥30, type and number 
of chosen deficits can vary between studies); total 
present divided by number of possible deficits
Range 0–1; sometimes categorised 
(threshold for frailty varies [eg, 0·2, 0·24])
16 Mortality (n=3); hospitalisation (n=1); 




& loss of weight scale
Five components (weight loss, fatigue, weakness, 
ambulation, illness, or comorbidity)
1–2 criteria: pre-frail; ≥3 criteria: frail 10 Mortality (n=4); hospitalisation (n=4); 
emergency department visit (n=2); 
disability (n=2); complications† (n=2); 
depression (n=1)
Clinical frailty scale Clinical tool based on functional status Ranges 1 (very fit) to 9 (terminally ill); 
some dichotomise frail as ≥5
5 Mortality (n=2); HbA1c (n=2); complications† 
(n=1)
Edmonton frailty scale Nine components: cognition, general health, functional 
independence, social support, medication, nutrition, 
mood, continence, and functional performance
Score 0–17; mild (7–8); moderate (9–10); 
severe frailty (≥11)
4 Complications† (n=2); depression (n=1); 
QOL (n=1)
Johns Hopkins adjusted 
clinical groups
Weighted comorbidity score identified from electronic 
medical records
Presence of frailty identified by specific 
indicator conditions
3 HbA1c (n=1); complications† (n=1)
Kihon checklist Self-administered checklist (components: activities of 
daily living, exercise, falling, nutrition, oral health, 
cognition, and depression)
Range 0–25; pre-frail (4–7); frail (≥8) 3 None
Comprehensive geriatric 
assessment
Multidisciplinary assessment, typically led by a 
geriatrician, aiming to reach a holistic assessment of 
health and wellbeing
Frailty identified by clinical judgement 
rather than predefined criteria
2 Hospitalisation (n=1); hypoglycaemia (n=1); 
complications† (n=1); depression (n=1); 
cognitive impairment (n=1); QOL (n=1)
Electronic frailty index Count of deficits identified from electronic medical 
records, based on the Frailty index approach
Mild (0·12–0·24); moderate (0·24–0·36); 
severe frailty (>0·36)
2 HbA1c (n=1); complications† (n=1)
Frailty risk class List of indicator conditions identified from electronic 
medical records
Presence of frailty identified by specific 
indicator conditions
2 Mortality (n=1)
Frailty risk score Count of 16 frailty risk factors (symptoms, behavioural 
factors, biomarkers, and nutritional factors)
Range 0–16 1 Mortality (n=1); hospitalisation (n=1); HbA1c 
(n=1)
Frailty staging system Seven components (disability, mobility, cognition, 
vision, hearing, continence, and social support)
Range 0–7; mild (1) moderate (2–3); 
severe frailty (≥4)
1 Mortality (n=1); cognitive impairment (n=1)
Frailty trait score 12 items across seven components (nutrition, activity, 
nervous system, vascular system, weakness, endurance, 
and slowness)
Range 0–49 1 None
Gill index Composite of chair stand and walking speed tests Moderate (unable to carry out one element) 




15 items across four domains (physical, cognitive, social, 
and psychological)
Range 0–15; ≥4 indicates frailty 1 None
Modified physical 
performance test
Nine item instrument assessing physical tasks Range 0–36; moderate (22–29); 
severe frailty (≤21)
1 Complications† (n=1)
QFrailty Algorithm based on electronic medical records 
combining mortality (QMortality score) and hospital 
admission (QAdmission score) risk
Categorised as mild, moderate, and severe 
frailty
1 None
RAND-36 questionnaire Physical function sub-scale of the RAND-36 quesionnaire Range 0–100; score <80 taken to indicate 
frailty
1 Mortality (n=1); complications† (n=1)
Study of osteoporotic 
fracture frailty indicator
Three components (weight loss, chair stand, and 
exhaustion)
One component: pre-frail; two to 
three components: frail
1 None‡
Vulnerable elders survey 
(VES-13)
Telephone questionnaire with 13 components (age, 
self-rated health, physical function, and disability)
Score ≥4=frail 1 HbA1c (n=1); complications† (n=1)
HbA1c=glycated haemoglobin. QOL=quality of life. *Three studies using these measures assessed more than one measure. †Diabetes-specific outcomes or complications (ie, microvascular or macrovascular). 
‡These studies considered prevalence of frailty only (ie, they did not assess the association between frailty and any other outcome). 
Table: Frailty measures in included studies
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a subgroup of the study population. Eight (7%) studies 
assessed specific ethnic groups (one study with African 
Americans, six studies with three different cohorts of 
Mexican Americans, and one study with Aboriginal 
Australians). A wide variety of frailty measures (either 
validated or well described) were used in the included 
studies: 20 different measures in total (table). The frailty 
phenotype was used in 69 (58%) studies; however, in 
51 (74%) of these studies the definition of one or more of 
the five frailty criteria differed from the original description 
from the Cardiovascular Health Study.11 The frailty index 
(16 [14%] studies) and FRAIL scale (10 [8%] studies) were 
also used. The remaining 23 studies used other measures 
of frailty (table).
In the 118 included studies, the median number of 
people with diabetes was 205 (IQR 104–570). Study 
populations were heterogeneous. Mean age ranged from 
50·4 years to 88·0 years (median 72·8 [IQR 69·6–74·4]). 
Eight (9%) of 88 community-based studies analysed 
adults of any age. Of these 88 studies, 72 (82%) sampled 
people above a specified age cutoff (most commonly aged 
60 [ten studies] or 65 years [39 studies]). Eight (9%) of 
88 studies assessed specific age ranges, with three 
of these studies including middle-aged people (age 
ranges 37–73 years, 45–74 years, and 49–65 years). Most 
community-based studies were judged to be representative 
in terms of age and sex (determined by sampling 
methods, response rates and demographics of people 
included); however, very few reported differences between 
included participants and non-responders. 14 community-
based studies focused on specific populations (ie, 
four studies on men, two on women, and eight on specific 
ethnic groups). Whole population studies varied in their 
sampling method (household survey, postal invitation, 
stratified sampling, or routine data analysis) and in their 
exclusion criteria. For example, 81 (69%) of 118 excluded 
individuals who were institutionalised (eg, living in 
residential care or nursing homes), people with restricted 
mobility (unable to attend an assessment), people with 
cognitive impairment, or people with specific disorders 
(eg, neurological con ditions such as Parkinson’s disease 
or stroke, often when the study included assessments of 
mobility or functional status). As many of these factors 
have established associations with frailty, it is likely that 
variation in these population characteristics will influence 
the estimated prevalence of frailty in the studies.
The prevalence of frailty in people with diabetes is shown 
in figure 2, with estimates from each study expressed as a 
proportion (with 95% CIs). Results are stratified by setting 
0 25 50 75 100
Hubbard et al, 2010 (83·3 years)
Carneiro et al, 2016 (74·0 years)
Chao et al, 2018 (56·4 years)
de Leon Gonzalez et al, 2016 (67·0 years)
Merchant et al, 2017 (71·2 years)
Woo et al, 2019 (74·7 years)
Li et al, 2018 (NA years)
Aguayo et al, 2019 (70·0 years)
Tang et al, 2013 (70·1 years)
Castrejon−Perez et al, 2018 (70·3 years)
Chhetri et al, 2017 (70·5 years)
Ferri−Guerra et al, 2019 (72·87 years)
Hanlon et al, 2018 (62·0 years)
Thein et al, 2018 (66·0 years)
Ng et al, 2014 (66·7 years)
Danon−Hersch et al, 2012 (67·0 years)
Wu et al, 2018 (67·0 years)
Mohr et al, 2007 (67·9 years)
Vaingankar et al, 2017 (69·0 years)
Orkaby et al, 2019 (69·7 years)
Kitamura et al, 2019 (71·0 years)
Crow et al, 2018 (71·1 years)
Ricci et al, 2014 (71·9 years)
Moreira et al, 2016 (72·0 years)
Watanabe et al, 2017 (72·1 years)
Cakmur et al, 2015 (72·7 years)
Nguyen et al, 2019 (72·8 years)
Sirola et al, 2011 (73·0 years)
Chen et al, 2010 (73·3 years)
Li et al, 2019b (73·3 years)
Chen et al, 2014 (73·4 years)
Pollack et al, 2017 (73·4 years)
Fried et al, 2001 (73·6 years)
Lee et al, 2017 (73·6 years)
Calado et al, 2016 (73·9 years)
Lahousse et al, 2014 (74·0 years)
Lin et al, 2015 (74·0 years)
Moreira et al, 2017 (74·0 years)
Avila-Flunes et al, 2008 (74·1 years)
Chang et al, 2010 (74·15 years)
Chaves et al, 2005 (74·3 years)
Ottenbacher et al, 2009 (74·3 years)
Cesari et al, 2006 (74·8 years)
Al Snih et al, 2009 (75·0 years)
Cigolle et al, 2009 (75·0 years)
Nadruz et al, 2017 (75·6 years)
Veronese et al, 2017 (76·2 years)
Weinstein et al, 2018 (77·2 years)
Bello−Chavolla et al, 2017 (77·7 years)
Castrejon−Perez et al, 2012 (77·9 years)
Wong et al, 2010 (79·6 years)
Vaz Fragozo et al, 2009 (84·3 years)
McClure et al, 2019 (70·2 years, SPPB)
Motokawa et al, 2018 (73·3 years, Kihon)
Khan et al, 2013 (73·6 years, HABC)
Cacciatore, 2013 (74·3 years, Frailty staging system)
McAllister et al, 2016 (50·4 years, Johns Hopkins ACG)
McAllister et al, 2017 (53·9 years, Johns Hopkins ACG)
Simpson et al, 2016 (60·0 years, Johns Hopkins ACG)
McAllister et al, 2018 (61·7 years, eFI)
Wang et al, 2017 (74·6 years, Frailty risk class)
Hippisley−Cox et al, 2017 (75·3 years, QMortality)
MacKenzie et al, 2019 (81·4 years)
Li et al, 2015 (80·0 years)
Molist−Brunet et al, 2019 (86·1 years)
Khanderwal et al, 2012 (66·4 years)
Wu et al, 2009 (77·0 years)
Xue et al, 2019 (78·5 years)
Lekan et al, 2018 (70·1 years, Frailty risk score)
Matsuzawa et al, 2010 (72·8 years, CGA)
Atif et al, 2019 (64·0 years)
Yanagita et al, 2018 (78·3 years)
Adame Perez et al, 2019 (70·0 years)
Boas et al, 2018 (NA years)
Liccini et al, 2016 (64·9 years)
da Silva et al, 2015 (68·7 years)
Nguyen et al, 2019b (69·5 years)
Azmon et al, 2018 (70·3 years)
Tepper et al, 2018 (70·6 years)
Anjos et al, 2017 (71·0 years)
Aguilar−Navarro et al, 2019 (73·0 years)
Chang et al, 2012 (74·6 years)
Tamura et al, 2018 (78·0 years)
Tuttle et al, 2018 (57·0 years, mPPT)
Nishimura et al, 2019 (70·2 years, Kihon)
van Hateren et al, 2015 (72·3 years, RAND−36)
Nelson et al, 2007 (78·0 years, VES−13)
Hasan et al, 2017 (76·8 years, Gronigen)
Ambagtsheer et al, 2019 (88·0 years, eFI)


























Figure 2: Prevalence of frailty by setting and frailty definition, ordered by 
mean age of study population
Full list of references of all the studies mentioned is included in the 
appendix (p 46). eFI=electronic frailty index. ACG=adjusted clinical groups. 
CGA=comprehensive geriatric assessment. VES-13=vulnerable elders survey 
RAND-36=research and Development Corporation. Kihon=kihon checklist. 
mPPT-modified physical performance test. Gronigen=Gronigen frailty indicator.
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and frailty definition and ordered by mean age of the study 
population. Prevalence estimates varied widely. Median 
community frailty prevalence using frailty phenotype was 
13% (IQR 9–21). Studies with a lower mean age tended to 
show lower frailty prevalence, particularly those studies 
without a lower age cutoff. However, prevalence was mixed 
even among populations with similar mean age and using 
the same frailty measure (particularly in community-based 
studies using the frailty phenotype). These differences in 
results might reflect a combination of differences in the 
under lying population, variation in exclusion criteria and 
in methods of recruitment affecting representativeness of 
the sample, and differences in how frailty components 
were specified.15 Three (3%) of 118 studies used both the 
frailty index and frailty phenotype.16–18 In each of these 
studies, the percentage of people identified as frail was 
higher using the frailty index (53%, 30%, and 32%)16–18  
compared to using the frailty phenotype (23%, 26%, and 
24%),16–18 highlighting the sensitivity of frailty prevalence to 
the measure used. Frailty prevalence was also notably high 
in some ethnic groups (eg, African Americans and 
Aboriginal Australians) and lower in others (eg, Mexican 
Americans).4,19,20
Diabetes was consistently associated with frailty 
prevalence after adjustment for age, sex, and other risk 
factors. Furthermore, diabetes was associated with a 
greater degree of frailty when assessed using the frailty 
index.
Eight (9%) of 88 community-based studies assessed the 
incidence of frailty, all using the frailty phenotype, among 
0·5 1·0 2·0 4·0
Negative association 
between diabetes and incident frailty
Positive association 
between diabetes and incident frailty
Author, year
Brunner et al, 201821
Cheong et al, 201922
Chhetri et al, 201723
Doi et al, 201824
Espinoza et al, 201025
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Figure 3: Random-effects meta-analysis of odds of incident frailty associated with diabetes 
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people who did not meet criteria for frailty at baseline. In 
each of these studies, diabetes was included as one of a 
range of baseline factors associated with the development 
of frailty. Meta-analysis of these studies shows that 
diabetes was consistently associated with the development 
of frailty (pooled odds ratio 1·48 [95% CI 1·33–1·64]; 
figure 3). Heterogeneity between study estimates was low 
(I²=0%) despite variation in the length of follow-up and 
the variables in each model. The only study16 assessing 
the association between HbA1c and changes in frailty 
status showed that a higher HbA1c at baseline was 
associated with worsening frailty over a 10-year period 
measured using the frailty index. Three studies (3%) of 
118 assessed transitions between frailty phenotype states 
and found that people with diabetes were less likely to 
improve from a frail to a pre-frail or robust state compared 
to people without diabetes.29,30,31 Together, these data 
provide evidence that diabetes, and perhaps poor 
glycaemic control, are risk factors for the development 
and persistence of frailty.
14 (12%) of 118 studies, using eight different frailty 
measures, assessed the relationship between frailty and 
all-cause mortality in people with diabetes. Eight of these 
used time-to-event analyses and were included in a meta-
analysis, with each frailty measure as a separate sub group 
(figure 4). Frailty was consistently associated with mortality 
(pooled hazard ratio 1·51 [95% CI 1·30−1·76]); however, 
the relative effect size varied considerably between studies 
using different frailty measures (I²=88% showing high 
heterogeneity).
Studies varied in length of follow-up, covariate adjust-
ment, and method of mortality assessment, limiting 
comparison of the absolute mortality rates associated 
with frailty in diabetes. However, the absolute mortality 
rate associated with frailty clearly differed between 
studies. In one study,40 hospitalised older patients with 
diabetes and frailty, according to the Clinical Frailty Scale, 
had a median life expectancy of 23 months. Mortality 
incidence in people with frailty was 60 per 1000 person-
years in one study using the frailty phenotype in Japan 
(mean age 72 years),32 and 161 per 1000 person-years in 
another study using the FRAIL scale in Taiwan (mean age 
71 years).37 Crude mortality rates in three different studies 
at 10-year follow-up were 50% using the frailty risk class,38 
68% using the frailty phenotype,33 and 96% using the 
frailty staging system.39
Frailty is therefore consistently associated with all-
cause mortality in people with diabetes. However, the 
method used to assess frailty, along with the underlying 
population, can lead to wide variation in both the relative 
and absolute risk of mortality in people identified as 
frail.
Studies assessing frailty and health-care utilisation are 
summarised in figure 5. Details on study methods and 
effect sizes are presented in the appendix (p 24). Frailty was 
consistently associated with increased risk of hospital-
isation and with emergency department visits in people 
with diabetes.
Frailty was consistently associated with disability in 
five (4%) of 118 studies.4,33,34,41,42 Three of these were 
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cross-sectional, while two showed associations between 
frailty and incident disability over variable lengths 
of follow-up. Cross-sectional studies also showed 
associations between frailty and cognitive impairment 
(three [3%] studies), depression (three [3%] studies), 
and lower quality of life (three [3%] studies). 
The relationship between frailty and diabetes-specific 
characteristics are shown in figure 5.
Overall, there was little evidence of a relationship 
between frailty status and mean HbA1c. Two of four studies 
assessing low HbA1c and one of four studies assessing 
high HbA1c found that people with frailty were more likely 
to have particularly high or low HbA1c values.43,44 Frailty 
was associated with micro vascular and macrovascular 
complications. These studies were cross-sectional;36,41,45–47,48–53 
none assessed changes in HbA1c over time or prospective 
relationships between frailty and the development of 
complications. Two studies (2%),43,44 which identified 
frailty using electronic medical records, observed that frail 
people with overly tight glycaemic control (HbA1c <6·5%) 
tended to be prescribed hypoglycaemic agents and that 
these were rarely discontinued despite low HbA1c. No 
included studies assessed the relationship between HbA1c 
and clinical outcomes in people who were frail. One study 
assessed the relationship between frailty and hypo-
glycaemic episodes.45 Frailty, identified by multi disciplinary 
comprehensive geriatric assessment, was associated with 
a higher incidence of hypoglycaemic episodes, as well as 
greater risk of hospitalisation with hypoglycaemia. No 
studies using either epidemiological or clinical measures 
to identify frailty examined hypoglycaemia as an outcome.
No studies assessed the relationship between frailty 
and glycaemic variability or the relationship between 
HbA1c and clinical outcomes in the context of frailty.
Discussion
This systematic review synthesised data from 118 studies 
from 18 high-income, five upper-middle-income, and 
three lower-middle-income countries that assessed the 
relationship between frailty and diabetes. Frailty was 
measured using a range of different scales, incorporating 
different constructs and developed for different pur-
poses. However, across all measures used, frailty was 
prevalent in community and hospital-based settings and 
associated with various adverse clinical outcomes, 
including mortality, hospitalisation, lower quality of life 
and dis ability. In community settings, studies showed 
that frailty prevalence can be expected to lie between 10% 
and 25% in people with diabetes older than 60 years. 
Frailty was also present in people younger than 65 years, 
although this was only examined in six studies. Frailty 
also appears to be more common in some ethnic groups 
(eg, Aboriginal Australians and African Americans) 
although this was only examined in eight studies. 
Diabetes was also associated with the development 
and progression of frailty. There were cross-sectional 
associ ations between frailty and microvascular and 
macrovascular complications but not higher mean HbA1c. 
This is notable as clinical guidelines recommend higher 
HbA1c targets in people with frailty.5
Clinicians managing diabetes will encounter frailty 
regardless of clinical setting. In clinical contexts, a nuanced 
approach that involves differentiating between levels of 
frailty and understanding individual patient needs and 
priorities within the context of frailty is likely to be 
important, rather than a one-size-fits-all approach to identi-
fying frailty. The identification and assessment of frailty 
should become part of routine management of people with 
diabetes. The included studies show that frailty can also 
be present in younger people with diabetes, including 
people younger than 65 years. However, the prognostic 
implications of frailty in diabetes at younger ages have not 
been examined.
Our findings show that diabetes is a risk factor 
for the development and progression of frailty. Possible 
mechanisms include accelerated muscle loss and 
sarcopenia in diabetes,54 along with neuropathic 
and inflam matory mechanisms,55 and shared cardio-
vascular risk factors.56 There is emerging evidence that 
nutritional and exercise-based interventions can limit 
the development of frailty in community settings.57 
However, diabetes was not considered or analysed 
separately in these studies; therefore, people with 
diabetes would have been eligible for inclusion, but the 
findings relate to the population in general and not to 
diabetes specifically. Non-pharmacological management 
of diabetes might be synergistic with efforts to prevent 
the development of frailty. Measuring frailty at baseline 
and as an outcome in trials of diabetes interventions 
would be an important step in under standing if and 
how interventions might mitigate frailty.
The importance of frailty is recognised in several 
national and international diabetes guidelines.5,6,58 Specifi-
cally, more relaxed HbA1c targets are recommended, 
and the risks of hypoglycaemia are highlighted.6,58 An 
international position statement on frailty in diabetes 
recommended aiming for the tightest control that could 
be achieved, while minimising the risk of hypoglycaemia.5 
In mild-to-moderate frailty a target of 7·0–8·0% 
was recommended and in severe frailty 7·5–8·5% was 
considered more protective.5 This review showed an 
association between frailty and HbA1c values that were 
either higher (ie, >9·0%) or lower (ie, <6·5%) than 
standard targets. Although higher values can be explained 
by higher targets, the association between frailty and low 
HbA1c values suggests that many patients with diabetes 
and frailty might be over-treated. People with frailty and 
excessively low HbA1c were prescribed hypoglycaemic 
drugs,45 which tended not to be discontinued over time.43 
Continuing hypoglycaemic agents despite low HbA1c 
could put people with frailty at greater risk than if these 
agents were discontinued.
It is also notable that only one study45 in this Review 
quantified the risk of hypoglycaemia in frailty, suggesting 
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that the association between current models of frailty and 
hypoglycaemia has largely been unquantified. The guide-
line recom mendations are generally based on the high 
proportion of older people among those presenting with 
hypo glycaemic complications,59,60 as well as data from trials 
such as ACCORD61 in which older patients (>80 years) had 
particularly high rates of hypoglycaemia when randomly 
assigned to the inter vention groups. Although this 
provides evidence of the greater risk of hypoglycaemia, 
particularly in older people, it is not clear if current 
measures of frailty accurately identify people at greatest 
risk of hypo glycaemia. Several of the included studies 
identified frailty in relatively young people with diabetes; 
however, it is not clear if frailty is associated with similar 
risks of hypoglycaemia in younger populations. Because 
the choice of frailty measure, and the way it is implemented 
has considerable influence over the population that is 
identified as frail,15 it is not clear how best to identify people 
with diabetes and frailty who are most likely to benefit 
from these recommendations around HbA1c targets.
Greater consistency in how frailty is measured and 
reported would improve our understanding of the 
implications of frailty. However, as frailty is a complex 
and multifaceted state, broad agreement on a single 
definition is unlikely.2,8 Translation to clinical practice is 
a key consideration in analysis of frailty because the 
most frequently used epidemiological measures (such 
as the Frailty Phenotype) are rarely incorporated into 
routine health care. The high prevalence and clinical 
importance of frailty in diabetes are clear, and there is 
therefore a need to advance our understanding of how 
frailty in diabetes should be managed. To do so will 
mean explicitly measuring frailty in diabetes trials 
and interventions. Such measurement is particularly 
important as recommendations for the management of 
diabetes in the context of frailty are based on studies in 
which frailty was not directly quantified. Because of the 
variation in how frailty is measured, there is a risk that 
recommendations will be applied inconsistently, and 
perhaps inappropriately, in clinical practice. Frailty-
specific evidence in the context of diabetes is required to 
refine the management of people living with frailty.
Our review used a comprehensive search strategy 
supplemented by hand-searching of relevant literature. 
However, our search was limited to studies published in 
English and excluded grey literature and conference 
abstracts, which could result in language or publication 
bias. Because the included studies were observational in 
nature, the relationships between diabetes and frailty 
cannot be assumed to be causal. There was considerable 
heterogeneity between included studies, in terms of 
inclusion criteria and representativeness (introducing 
potential selection bias), frailty measures (validated vs 
adapted), adaptation of frailty criteria, and study settings. 
Although we explored the effect on frailty prevalence of 
some of these factors, we were limited by the reporting 
of these in the included studies and the variable level of 
detail provided, particularly around non-response rates 
and completeness of follow-up data. It was therefore not 
possible to specify which factors drove the heterogeneity 
in prevalence estimates.
Frailty identification, assessment, and management 
should be part of routine diabetes care, which will require 
integration and embedding of frailty assessment tools into 
existing templates and protocols. Frailty is not a homo-
genous entity, and the prognosis and implications of frailty 
are likely to differ depending on the level of frailty and how 
it is defined, as well as by other factors such as age. 
Management must therefore be tailored to the individual. 
A nuanced and consistent understanding of frailty is 
needed to inform the evi dence base. There is a need to 
examine the differential consequences of frailty in different 
sub-populations (such as younger people and people from 
different ethnic groups). Future research should also focus 
more on lower-income and middle-income countries, in 
which diabetes and ageing are growing public health 
concerns. Finally, despite guidelines calling for lower 
glycaemic targets in people with diabetes and frailty, HbA1c 
is below target in many people. Longitudinal assessments 
of the consequences of glycaemic control in the context of 
frailty are largely absent from literature. These gaps should 
be addressed to improve management of people living 
with diabetes and frailty.
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